Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 86352 refers to a cellular function assay that is designed to evaluate the functionality of cells through a specific testing process. This assay involves the use of live cell cultures, which are essential for accurately assessing cellular responses. In this procedure, cells are subjected to stimulation using agents known as mitogens or antigens. These agents provoke a response from the cells, allowing for the observation of their functional capabilities. Following stimulation, the cells are analyzed using various assay techniques, such as chemiluminescent assays, which are sensitive methods for detecting specific biomarkers. One of the key biomarkers measured in this assay is adenosine triphosphate (ATP), a molecule that plays a critical role in cellular energy transfer and is a vital indicator of cell viability and function. The detection and quantification of ATP levels provide valuable insights into the health and activity of the cells being studied, making this assay a crucial tool in both research and clinical settings for understanding cellular behavior and function.
© Copyright 2026 Coding Ahead. All rights reserved.
The cellular function assay coded as CPT® 86352 is indicated for use in various clinical and research scenarios where the assessment of cellular activity is necessary. The following conditions and situations may warrant the performance of this assay:
The procedure for conducting a cellular function assay as described by CPT® 86352 involves several key steps that ensure accurate measurement of cellular responses. Each step is critical to the integrity of the assay and the reliability of the results.
Post-procedure care for the cellular function assay primarily involves the analysis and interpretation of the results obtained from the assay. It is essential to ensure that the data is accurately recorded and analyzed to draw meaningful conclusions regarding cellular function. Additionally, any necessary follow-up actions based on the assay results should be planned, which may include further testing or adjustments in treatment protocols if the assay is used in a clinical context. Proper documentation of the assay results is also crucial for compliance and future reference.
| Short Descr | CELL FUNCTION ASSAY W/STIM | Medium Descr | CELLULAR FUNCTION ASSAY STIMUL&DETECT BIOMARKE | Long Descr | Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 235 - Other Laboratory |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GZ | Item or service expected to be denied as not reasonable and necessary | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Changed | Medium Descriptor changed. |
| 2011-01-01 | Changed | Short description changed. |
| 2010-01-01 | Added | - |
Get instant expert-level medical coding assistance.